Quavonlimab
- Generic Name
- Quavonlimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2254059-25-9
- Unique Ingredient Identifier
- GG0AN49Y59
- Background
Quavonlimab is under investigation in clinical trial NCT03179436 (Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)).
- Associated Conditions
- -
- Associated Therapies
- -
Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 200
- Registration Number
- NCT04305041
- Locations
- 🇮🇱
Chaim Sheba Medical Center ( Site 1701), Ramat Gan, Israel
🇫🇷A.P.H. Paris, Hopital Saint Louis ( Site 1107), Paris, France
🇫🇷Hopital Saint Andre ( Site 1108), Bordeaux, Gironde, France
A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2018-05-07
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 318
- Registration Number
- NCT03516981
- Locations
- 🇵🇱
Dolnoslaskie Centrum Onkologii. ( Site 0993), Wroclaw, Dolnoslaskie, Poland
🇨🇦Jewish General Hospital ( Site 0307), Montreal, Quebec, Canada
🇺🇸University of California Davis Comprehensive Cancer Center ( Site 0137), Sacramento, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath